Cardiovascular Medicine Book

//fpnotebook.com/

Preeclampsia Prevention

Aka: Preeclampsia Prevention, Preeclampsia Prophylaxis, PIH Prophylaxis
  1. Indications: Preeclampsia risk factors
    1. High risks
      1. Autoimmune Disease (Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome)
      2. Preeclampsia in prior pregnancy
      3. Chronic Hypertension
      4. Diabetes Mellitus
      5. Renal disease
      6. Multiple Gestation
    2. Moderate risks
      1. Advanced maternal age (35 years old or older)
      2. Family History of Preeclampsia in a first degree relative (mother, sister)
      3. Black race
      4. Obesity (BMI >30 kg/m2)
      5. Nulliparity or more than 10 years between pregnancies
      6. History of Low Birth Weight Infant or adverse pregnancy outcome
      7. Low socioeconomic status
  2. Management: Aspirin 81 mg/day
    1. ACOG and USPTF Indications (to start in first trimester)
      1. One Preeclampsia high risk factor or two moderate risk factors (sere above)
      2. This replaces the older, more limited criteria focused on prior Preeclampsia in pregnancy
      3. (2018) Obstet Gynecol 132(1):e44-e52 +PMID:29939940 [PubMed]
    2. Protocol
      1. Aspirin 81 mg orally daily starting at 12-28 weeks (preferably by 16 weeks) and continued until delivery
    3. Efficacy: Benefits
      1. Prevents Pregnancy Induced Hypertension
      2. Prevents Intrauterine Growth Retardation
    4. Efficacy: Number Needed to Treat (NNT) to prevent one case of Preeclampsia
      1. NNT: 69 (overall)
      2. NNT: 18 (if highest risk factors present)
    5. References
      1. Coomarasamy (2003) Obstet Gynecol 101:1319-32 [PubMed]
  3. Management: Calcium Supplementation
    1. Dose
      1. Calcium 1-2 g orally daily
    2. Indications
      1. Dietary Calcium <600 mg/day
    3. Efficacy: Benefits
      1. Lowers Preeclampsia risk
      2. Lowers Blood Pressure
        1. Systolic lowered 5.4 mmHg
        2. Diastolic lowered 3.4 mmhg
    4. Reference
      1. Bucher HC (1996) JAMA 275:1113-7 [PubMed]
  4. Management: Agents to avoid due to low efficacy
    1. Avoid routine Magnesium Supplementation
    2. Avoid routine Omega-3 Fatty Acid Supplementation
    3. Avoid antioxidant Vitamin Supplementation
  5. References
    1. (2019) Am Fam Physician 100(10): 649-50
    2. Fontaine (2000) in ALSO, B:1-36
    3. Sibai in Gabbe (2002) Obstetrics, p. 945-74
    4. (2000) Am J Obstet Gynecol 183(1):S1-22 [PubMed]
    5. Zamorski (2001) Clin Fam Pract 3:329-47 [PubMed]

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree